INC Research Receives iCardiac Site Certification

INC Research announced it is now certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in Phase I clinical development. INC’s use of iCardiac Early Precision QT technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) study, which can cost between $2 million and $5 million for its clients.

Read the full release.